{"id":"doi:10.1056/nejmoa2501006","kind":"article","title":"Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes","authors":["Darren K. McGuire","Nikolaus Marx","Sharon L. Mulvagh","John Eric Deanfield","Silvio E. Inzucchi","Rodica Pop‐Busui","Johannes F.E. Mann","Scott S. Emerson","Neil R Poulter","Mads D.M. Engelmann","Maria Sejersten Ripa","G. Kees Hovingh","Kirstine Brown‐Frandsen","Stephen Charles Bain","Matthew Aaron Cavender","Mette Gislum","Jens‐Peter David","John B. Buse"],"author_count":18,"year":2025,"published":"2025-03-29","venue":"New England Journal of Medicine","cited_by":415,"doi":"10.1056/nejmoa2501006","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1056/nejmoa2501006","archive_url":"https://space-kitty.com/papers/doi:10.1056/nejmoa2501006","updated":null,"pmid":"40162642","pmcid":null,"openalex_id":"W4408960945","pdf_url":null,"abstract":null,"abstract_license":null,"license":null,"is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Diabetes Treatment and Management"],"details":null,"provenance":"openalex","attribution":"Metadata and citation counts: OpenAlex (CC0).","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[{"slug":"glp1-metabolic","title":"GLP-1 & Incretin Therapies: State of the Field (October 2026)","url":"https://space-kitty.com/dossiers/glp1-metabolic"}]}